AI Article Synopsis

  • Axillary lymph node dissection (ALND) is common for breast cancer patients with sentinel lymph node (SLN) metastasis, but many patients do not benefit since most have no further metastases in the axilla.
  • Researchers developed predictive nomograms to identify which patients are at high risk (>50%) for non-SLN metastasis, suggesting who might benefit from additional axillary treatment.
  • The study analyzed data from 1000 patients, showing that those with a high predicted risk had significantly higher metastasis rates, yet the nomograms had varying predictive values (44%-64%) and were notably less effective for high-risk patients, highlighting the need for better predictive models.

Article Abstract

Although axillary lymph node dissection (ALND) has been the standard intervention in breast cancer patients with sentinel lymph node (SLN) metastasis, only a small proportion of patients benefit from this operation, because most do not harbor additional metastases in the axilla. Several predictive tools have been constructed to identify patients with low risk of non-SLN metastasis who could be candidates for the omission of ALND. In the present work, predictive nomograms were used to predict a high (>50 %) risk of non-SLN metastasis in order to identify patients who would most probably benefit from further axillary treatment. Data of 1000 breast cancer patients with SLN metastasis and completion ALND from 5 institutions were tested in 4 nomograms. A subset of 313 patients with micrometastatic SLNs were also tested in 3 different nomograms devised for the micrometastatic population (the high risk cut-off being 20 %). Patients with a high predicted risk of non-SLN metastasis had higher rates of metastasis in the non-SLNs than patients with low predicted risk. The positive predictive values of the nomograms ranged from 44 % to 64 % with relevant inter-institutional variability. The nomograms for micrometastatic SLNs performed much better in identifying patients with low risk of non-SLN involvement than in high-risk-patients; for the latter, the positive predictive values ranged from 13 % to 20 %. The nomograms show inter-institutional differences in their predictive values and behave differently in different settings. They are worse in identifying high risk patients than low-risk ones, creating a need for new predictive models to identify high-risk patients.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-012-9553-5DOI Listing

Publication Analysis

Top Keywords

risk non-sln
16
lymph node
12
breast cancer
12
patients
12
cancer patients
12
predicted risk
12
patients low
12
non-sln metastasis
12
predictive values
12
predictive tools
8

Similar Publications

: In this paper, we investigate the association of glycoprotein 96 (GP96) and androgen receptor (AR) expression with clinicopathological factors, additional axillary lymph node burden, and their potential role in predicting 5-year overall survival (OS) and disease-free survival (DFS) in breast cancer (BC) patients with sentinel lymph node (SLN) involvement. We also explore the prognostic value of the presence of extranodal extension (ENE) in SLN. : We retrospectively enrolled 107 female patients with cT1-T2 invasive BC and positive SLN biopsy.

View Article and Find Full Text PDF
Article Synopsis
  • Sentinel lymph node biopsy (SLNB) is standard for early breast cancer patients, revealing significant non-sentinel lymph node (non-SLN) metastasis rates, impacting treatment choices.
  • A study of 892 female patients showed that 56.5% with positive sentinel lymph nodes had non-SLN metastasis, with rates increasing alongside the number of positive SLNs.
  • Findings indicated that non-SLN metastasis is linked to various factors like tumor size and grade, suggesting that precise staging can guide more effective treatment strategies for breast cancer patients.
View Article and Find Full Text PDF

Background/aim: This study aimed to identify the risk factors associated with non-sentinel lymph node (non-SLN) metastasis in case of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with cN0 on preoperative exam, where the sentinel lymph node (SLN) is positive.

Patients And Methods: We conducted a retrospective review of medical records from the Chonnam National University Hwasun Hospital, spanning from January 2013 to January 2020, focusing on patients with HR+, HER2- breast cancer. Specifically, we collected the clinical and pathological data for those patients who underwent axillary lymph node dissection (ALND) due to positive SLN.

View Article and Find Full Text PDF

Background: Cervical cancer is the fourth most common cause of malignant tumor-related deaths among women in developing nations. Cervical cancer has been estimated to cause 527.600 new cases and 265.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the clinical outcomes of localized prostate cancer patients undergoing radical laparoscopic prostatectomy with sentinel lymph node biopsy (SLNB) and pelvic lymph node dissection, focusing on recurrence-free survival (RFS).* -
  • Out of 231 patients studied, 16.5% were found to have positive sentinel lymph nodes, with significant implications for their prognosis, suggesting that knowing the status of SLNs is crucial for patient management.* -
  • The findings indicated that RFS is significantly higher in patients with negative SLNs compared to those with positive SLNs, highlighting the importance of SLNB in predicting clinical outcomes in intermediate- and high-risk prostate cancer.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!